Decreased Viral Load And Symptoms Of Polyomavirus-Associated Chronic Interstitial Cystitis After Intravesical Cidofovir Treatment
Main Category: Urology / NephrologyArticle Date: 14 Apr 2009 - 1:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
UroToday.com - The role of reactivation of latent infection with the ubiquitous polyomaviruses in the causation of chronic interstitial cystitis has not yet been described. The polyomaviruses BK virus and JC virus are ubiquitous urinary tract colonizers in early life, but they rarely cause disease in immunocompetent individuals.
Polyomaviruses are excreted intermittently in the urine in healthy, asymptomatic adults. Dr. Damon Eisen and colleagues from Melbourne, Australia analyzed urinary polyomavirus shedding in hosts without severely compromised immune systems and with BPS/IC.
Two patients with cystoscopic appearances typical of BPS/IC were found to have persistent polyomavirus urinary infection through urinary cytological testing.
One patient was a 60-year-old white man who was relatively immunocompromised as a result of polyglandular autoimmune syndrome, manifested by type 1 diabetes, vitiligo, and pernicious anemia. He had a 4-year history of symptoms typical of BPS. Results of repeated urinary cytological analysis and quantitative PCR for polyomavirus DNA during a 10-month period showed evidence of polyomavirus infection with urinary viral loads greater than 108 copies/ml. A trial of intravesical cidofovir was begun resulting in resolution of symptoms and decrease in viral load that was sustained over 8 months.
A second patient, a 48-year-old Chinese woman with a 10-year history of BPS/IC symptoms and typical cystoscopic picture, had been treated with norfloxacin and had very low polyomavirus levels in the urine. Her symptoms gradually improved over 2 years of follow-up.
The authors note that serological evidence of BK virus is found in 85% of adults. Rates of urinary polyomavirus shedding may increase to 60% with pregnancy, older age, or immune dysfunction. Fluroquinolones appear to have anti-BKV activity. Further work is required to better define the role of polyomaviruses in BPS/IC pathogenesis. Dr. Eisen concludes that real-time studies will have the highest likelihood of demonstrating direct infection of the bladder. If additional evidence accumulates that shows BKV to be a cause of BPS/IC, further investigation of intravesical cidofovir would be warranted.
Eisen DP, Fraser IR, Sung LM, Finlay M, Bowden S, O'Connell H
Clin Infect Dis. 2009 May 1;48(9):e86-8
10.1086/597827
Written by UroToday.com Contributing Editor Philip M. Hanno, MD, MPH
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2009 - UroToday
Visit our urology / nephrology section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/145885.php>
APA
http://www.medicalnewstoday.com/releases/145885.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



